Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
The medicine for type 2 diabetes called Ozempic is, without a doubt, Novo Nordisk's (NYSE: NVO) knight in shining armor. Thanks to an impressive amount of demand and the company's dedicated efforts in exploring other conditions that the medicine could potentially treat, there looks to be an abundance of upside remaining for investors.
A chunk of that possible upside just got one big step closer to being made real. Here's why the investment opportunity is even more bullish than it was before.
Chronic kidney disease (CKD) entails a progressive loss of kidney functionality that eventually becomes so severe that it causes heart problems, among many other issues. According to Maximize Market Research, the market for CKD medicines will grow to reach a size of $19.2 billion by 2030.
Source Fool.com
